This grant studies the efficacy of novel drugs that target Prohibitins and pro-survival proteins associated with hematological cancers, such as leukemia and lymphoma; and explores new options to identify oncogenic mutations and their association with the activation of anti-apoptotic proteins in primary patient samples.
Posting date: Thu, 04/19/2018
Award start date: Fri, 06/01/2018
Award end date: Thu, 01/31/2019
